GlassScriptPhysician profile
Samuel Marino
NPI 1932922606
$3,494.07
in general payments reported to CMS, 2019-2025
46 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $860 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,200 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,200.12 |
| Education | $293.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $543.67 | 2024-2025 | Rybrevant, Tecvayli, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $217.75 | 2024-2025 | |
| Sobi, INC | $186.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $183.75 | 2024-2025 | Imfinzi, Enhertu, Farxiga |
| Merck Sharp & Dohme LLC | $164.97 | 2024-2025 | Keytruda, Capvaxive, Verquvo |
| Eisai INC. | $164.63 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $162.37 | 2024-2025 | Xpovio |
| Incyte Corporation | $113.83 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.28 | 2025 | Jardiance |
| Gilead Sciences, INC. | $101.04 | 2024-2025 | Trodelvy |
| Seagen INC. | $99.95 | 2025 | |
| Novartis Pharmaceuticals Corporation | $98.95 | 2025 | |
| Cvrx, INC. | $94.38 | 2025 | Barostim Neo System |
| Puma Biotechnology, INC. | $88.62 | 2024-2025 | |
| Abbvie INC. | $88.21 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $74.95 | 2024-2025 | Loqtorzi |
| Lilly USA, LLC | $74.28 | 2024-2025 | Jaypirca, Verzenio |
| Amgen INC. | $70.86 | 2025 | Repatha |
| Beigene USA, INC. | $64.26 | 2024-2025 | Tevimbra |
| Rigel Pharmaceuticals, INC. | $58.52 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Taiho Oncology, INC. | $54.58 | 2024-2025 | |
| Genzyme Corporation | $49.93 | 2024-2025 | |
| Legend Biotech USA INC. | $46.60 | 2024-2025 | Carvykti |
| Regeneron Healthcare Solutions, INC. | $39.00 | 2024-2025 | Libtayo |
| Celgene Corporation | $38.96 | 2025 | Reblozyl |
| Pfizer INC. | $37.08 | 2025 | |
| Syndax Pharmaceuticals, INC. | $33.59 | 2025 | |
| Geron Corporation | $28.78 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $28.42 | 2024 | Besremi |
| Blueprint Medicines Corporation | $27.08 | 2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $26.70 | 2025 | Iclusig |
| Beone Medicines USA, INC. | $25.84 | 2025 | Tevimbra |
| Array Biopharma INC | $25.21 | 2025 | Braftovi, Mektovi, Tukysa |
| Bridgebio Pharma, INC. | $24.96 | 2025 | Attruby |
| Caris Mpi, INC. | $24.86 | 2025 | Mi Cancer Seek |
| Accord Healthcare, INC. | $24.63 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $24.32 | 2025 | Eliquis |
| Daiichi Sankyo INC. | $23.71 | 2025 | Enhertu |
| Genmab U.S., INC. | $23.35 | 2025 | Epkinly |
| Stemline Therapeutics INC. | $21.88 | 2025 | Orserdu |
| Genentech USA, INC. | $19.50 | 2025 | Polivy |
| Emd Serono, INC. | $18.42 | 2024 | |
| Kyowa Kirin, INC. | $17.80 | 2025 | |
| Sumitomo Pharma America, INC. | $15.96 | 2024 | Orgovyx |
| Esperion Therapeutics, INC. | $14.51 | 2025 | Nexlizet, Nexletol |
| Acrotech Biopharma INC. | $13.84 | 2025 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Marino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.